Development of a Research Agenda for the Management of Metastatic Colorectal Cancer: Proceedings from a Multidisciplinary Research Consensus Panel by d’Othée, Bertrand Janne et al.
Development of a Research Agenda for the Management of 
Metastatic Colorectal Cancer: Proceedings from a 
Multidisciplinary Research Consensus Panel
Bertrand Janne d’Othée, MD, MPH, Constantinos T. Sofocleous, MD, PhD, Nader Hanna, 
MD, Robert J. Lewandowski, MD, Michael C. Soulen, MD, Jean-Nicolas Vauthey, MD, 
Steven J. Cohen, MD, Alan P. Venook, MD, Matthew S. Johnson, MD, Andrew S. Kennedy, 
MD, Ravi Murthy, MD, Jean-Francois Geschwind, MD, and Stephen T. Kee, MD
Department of Diagnostic Radiology and Nuclear Medicine, Division of Vascular and 
Interventional Radiology (B.J.d.O.), and Department of Surgery, Division of Surgical Oncology 
(N.H.), University of Maryland School of Medicine; Department of Radiology and Radiological 
Science, Division of Vascular and Interventional Radiology (J.F.G.), Johns Hopkins University 
School of Medicine, Baltimore, Maryland; Department of Radiology, Division of Interventional 
Radiology (C.T.S.), Memorial Sloan-Kettering Cancer Center, New York, New York; Department 
of Radiology (R.J.L.), Northwestern University Feinberg School of Medicine and Northwestern 
Memorial Hospital, Chicago, Illinois; Department of Radiology (M.C.S.), Hospital of the University 
of Pennsylvania; Department of Medical Oncology, Division of Gastrointestinal Medical Oncology 
(S.J.C.), Fox Chase Cancer Center Partners, Philadelphia, Pennsylvania; Department of 
Diagnostic Radiology (R.M.) and Liver Service (J.N.V.), M. D. Anderson Cancer Center, 
University of Texas Medical School, Houston; Department of Medicine, Division of Medical 
Oncology (A.P.V.), University of California, San Francisco, San Francisco; Department of 
Radiological Sciences, Division of Interventional Radiology (S.T.K.), Ronald Reagan University of 
California, Los Angeles, Medical Center, Los Angeles, California; Department of Radiology and 
Imaging Sciences (M.S.J.), Indiana University School of Medicine, Indianapolis, Indiana; and 
Cancer Centers of North Carolina (A.S.K.), North Carolina State University, Raleigh, North 
Carolina
INTRODUCTION
Colorectal cancer (CRC), the second leading cause of cancer death in the United States, 
occurs in an estimated more than 145,000 patients annually, with almost 50,000 deaths each 
year. Metastatic liver disease is the cause of death in the majority of them (1,2). Liver-only 
metastases affect up to one half of patients with CRC (1,2), with approximately 15% (range, 
8%–26%) presenting synchronously (3,4) and an additional 15% found metachronously 
during the next 5 years (3). Colorectal liver metastases (CLMs) are resectable in 20%–25% 
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of patients only; some of the remaining 75%–80% may benefit from “downsizing” therapy, 
which can result in 10%–20% more patients becoming resectable. Overall survival rates in 
patients with either primarily or secondarily resectable CLMs can be as high as 58% at 5 
years and 15% at 10 years (5,6). Current front-line treatments available to improve 
downsizing and resectability include systemic therapies (chemotherapy with or without 
bevacizumab or cetuximab) and pre-operative portal vein embolization (PVE). Other 
approaches include local ablation therapies, regional intraarterial therapies with 
embolization (transcatheter arterial chemoembolization, or radio-embolization by selective 
internal radiation therapy with Yttrium 90-loaded microspheres) or infusion (ie, hepatic 
arterial infusion [HAI] pump chemotherapy), and external beam radiation therapy (RT). The 
role of these liver-targeted therapies to promote conversion from unresectable to resectable 
liver disease remains an evaluation in progress. For the majority of patients with 
unresectable CRC liver metastases, standard of care is first- and second-line triplet 
chemotherapy, which is associated with a median survival of 18–24 months (7–10). Multiple 
single-institution retrospective reports suggest the potential for improvement in survival 
time by the addition of liver-directed therapies such as chemoembolization, HAI, or 
radioembolization. This has not been prospectively evaluated in controlled trials, but could 
potentially represent a major development in Interventional Oncology (IO). The Society of 
Interventional Radiology (SIR) Foundation has identified the management of metastatic 
CRC (mCRC) as an emerging inter-ventional radiologic research priority and convened a 
Research Consensus Panel (RCP) Meeting on October 3, 2011 to establish a prioritized 
research agenda. This article reports the proceedings from this meeting.
METHODS
Panel Membership
In April 2011, the SIR Foundation sent to the SIR membership an invitation to submit 
applications to lead the RCP Meeting. A lead investigator was selected, who invited, in 
cooperation with the SIR Foundation, (i) a multidisciplinary group of expert panelists, (ii) 
representatives from governmental agencies, and (iii) representatives from industries 
involved in the IO field. The 13 expert panelists included eight interventional radiologists, 
two medical oncologists, two surgical oncologists, and one radiation oncologist, all with 
demonstrated relevant experience. Government agencies included the Food and Drug 
Administration (FDA; four representatives from the Center for Devices and Radiological 
Health and one from the Center for Drug Evaluation and Research) and the Agency for 
Healthcare Research and Quality (AHRQ; one representative from the Center for Outcomes 
and Evidence). Industry representatives came from major companies involved in the 
production and/or distribution in the United States of products for local or regional liver-
directed therapies.
Agenda Methodology
The stated objective of the RCP was to define a prioritized research agenda for the 
management of mCRC, including topics amenable to basic science/technology research, 
pilot clinical research, and multicenter clinical trials. The process involved several steps. 
First, each panelist gave a 10-minute presentation on an assigned topic in their field of 
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expertise providing an updated review of current knowledge on the outcomes of relevant 
therapies, using the AHRQ classification of levels of evidence (Table 1) (11). Panelists were 
also asked to include in their presentations descriptions of gaps in the current knowledge 
base, and recommendations for basic science and clinical research questions or projects that 
need further study. Specifically, panelists were asked to (i) define the most important 
clinical questions that could realistically be answered through pivotal multi-institutional 
clinical trials or registries, (ii) describe the most promising future directions that merit 
preclinical or early clinical exploration in the management of mCRC, and (iii) outline the 
critical alliances that must be developed to advance the prioritized research and how the SIR 
Foundation can best support these initiatives. A total of 12 presentations were given (11 
individual and one joint). Afterwards, a round-robin discussion was held to examine 
important research questions, potential opportunities for future research studies, and 
consolidate similar or redundant ideas into succinct titles of research projects that deserved 
prioritization. Thereafter, invited comments from government and industry representatives 
were heard. This step resulted in a consolidated list of research projects being voted on 
anonymously by each expert panelist: panelists were asked to rank from 1 (high priority 
score) to 5 (low priority) the five top IO priority topics. Government and industry 
representatives did not vote. Panelists’ scores were then added and topics were sorted by 
order of decreasing priority (increasing score) and further commented on. The top-priority 
topics (ie, those with the lowest scores) were selected as a basis for further study design. 
Applications in these areas of research are eligible for consideration for the SIR Foundation 
Funding Source Development Grant.
Panel Presentations
Natural history of, and National Comprehensive Cancer Network guidelines 
for, CRC liver metastases—The natural history of liver metastases from CRC differs on 
the basis of disease distribution, which reflects the presence of three distinct patient 
populations. Studies from the 1980s (12) demonstrated that, left untreated, patients with a 
solitary CLM, have survival rates of approximately 70% at 1 year and 45% at 2 years. These 
patients have better outcomes than those with multiple unilobar CLMs (65% survival at 1 y 
and 30% at 2 y) and those with multiple bilobar CLMs (40% survival at 1 y and 15% at 2 y). 
Survival rates decrease to lower than 5% at 3 years in the latter two groups and at 4.5 years 
in the former. In 2011, almost 30 years later, survival rates have dramatically improved to 
more than 60% at 2 years and approximately 35% at 5 years.
This improvement is attributed to the availability of numerous new chemotherapeutics and 
biologic agents and improved imaging and surgical techniques. The indications for surgery 
have changed as more impact is anticipated from these other treatments, resulting in an 
increase in the number of patients deemed potentially curable.
Accordingly, current Guidelines from the National Comprehensive Cancer Network 
(NCCN) (1,2) emphasize chemotherapeutic agents and put less emphasis on interventional 
technologies. Mainstream systemic therapies include systemic folinic acid/5-fluorouracil/
oxaliplatin, folinic acid/5-fluorouracil/irinotecan (FOLFIRI), capecitabine plus oxaliplatin, 
and other regimens, and multiple combinations with the antivascular endothelial growth 
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factor receptor agent bevacizumab or, in KRAS wild-type patients, one of the epidermal 
growth factor receptor inhibitors cetuximab or panitumumab. Few IO therapies are 
recommended in the NCCN Guidelines and, when mentioned, they are supported by level 3 
evidence only (ie, based on any level of evidence, there is major NCCN disagreement that 
the intervention is appropriate). They include (i) PVE before surgical resection; (ii) local 
ablation therapies, alone or in conjunction with surgical resection, when all disease foci 
appear treatable; and (iii) intraarterial hepatic embolization in chemotherapy-resistant or 
chemotherapy-refractory patients with liver only or liver-dominant disease.
Intraarterial hepatic infusion chemotherapy with or without systemic chemotherapy is also 
an available option in a few experienced centers (level 2B evidence), and is included mostly 
in footnotes of the NCCN Guidelines. Radioembolization is not included in these 
Guidelines. These gaps reflect an absence of well-done randomized studies with IO 
treatments as well as the belief that CRC, is for the most part, a systemic disease. Although 
it will be difficult to change this paradigm, well-done randomized studies testing the utility 
of locoregional therapies need to be conducted to establish the relevance of interventional 
therapies.
Surgical resectability and role of PVE—The major risk factor of perioperative 
morbidity, liver insufficiency, and mortality from partial hepatectomy is insufficient 
volume/function of the liver remnant. The current definition of resectability is based on the 
volume of the future liver remnant (FLR), which can ensure adequate liver function after 
major resection (13). Postoperative liver function is better evaluated by determining the 
volume of the FLR than the use of refined biochemical tests, liver biopsy, or the indocyanine 
green clearance test (14). In patients who are candidates for major resection, PVE is used to 
increase the size of the FLR by redirecting the portal venous flow to cause hypertrophy of 
the nonembolized parenchyma (typically the left hepatic lobe), thereby increasing the 
number of potential resection candidates. The liver remnant after partial hepatectomy should 
be at least 20% of the total liver volume in normal livers (15–17), 30% in cases of previous 
chemotherapy (18–21), and 40% in cases of diffuse liver disease or cirrhosis (19,22). Long-
term survival rates of CLM have been shown to be equivalent regardless of whether PVE 
had been performed (5-y survival rates of 34%–44% with PVE vs 37%–53% without) 
(16,19,23). Although PVE is supported only by level II-2 evidence, its adoption is increasing 
worldwide and the literature on this topic is growing accordingly. To standardize computed 
tomographic (CT) volumetry, a standardized FLR volume has been introduced (14), which 
is the ratio of the FLR to the total estimated liver volume (calculated based on body weight 
and body surface area). This ratio allows uniform comparison of FLR volume before 
resection with or without PVE. Variability in the technical performance of PVE remains 
large, with no proven superiority of any embolic agent.
Modern surgical approaches to increase resectability include the two-stage hepatectomy and 
the reverse approach, whereby the liver secondary tumors are resected before the colorectal 
primary tumor. Two-stage hepatectomy is a sequential approach dedicated to patients with 
multiple, bilobar CLMs that cannot be resected in a single procedure. It generally combines 
limited resection of lesions located in the FLR during the first stage followed 2–3 months 
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later by second-stage major hepatic resection (usually right or extended right hepatectomy). 
A PVE may be included in this strategy, and it is performed between the two stages.
The classical approach to synchronous CLM includes resection of the primary bowel tumor 
followed by resection of the CLM at a second operation. The main concern with this 
approach is the delay in treatment of the CLM. A second strategy combines the resection of 
the CLM and the primary tumor at the same operation, avoiding delayed treatment of CLM. 
This combined approach can only be offered in selected patients with synchronous CLM 
(24) as the risk of postoperative complications increases when associated with major liver 
resection (25). An alternate option in patients without an obstructive primary CRC is the 
reverse approach, with resection of the liver first followed by resection of the primary tumor 
during a second procedure (26).
Prediction of outcomes after surgical resection—Until recently a risk score based 
on clinical criteria (carcinoembryonic antigen level, lymph node status of primary tumor, 
disease-free interval between resection of primary tumor and metastasis, tumor size, number 
of metastases) was used to predict outcome after hepatic metastasectomy (27). Pathologic 
response, defined as the ratio of viable tumor cells to the total tumor surface area, is a novel 
alternate predictor of survival after resection of CLM (28). Response evaluation criteria in 
solid tumors (RECIST) do not accurately predict pathologic response or survival following 
resection of CLM (29). In as many as 50% of patients receiving combined chemotherapy 
(irinotecan and oxaliplatin) and bevacizumab, CLMs undergo morphologic changes and 
show a cyst-like appearance with a sharp tumor/liver interface and complete resolution of 
peripheral rim enhancement, if initially present. This optimal morphologic radiologic 
response correlates with pathologic response and is predictive of survival in medical and 
surgical patients with CLM (29).
Surgical outcomes of CRC hepatic metastasectomy—Surgical resection of all 
metastases remains the only option that enables prolonged survival, with 5-year survival 
rates up to 50% or greater (30), whether used alone or in conjunction with local ablation 
and/or PVE. In patients with resectable CLM, only one randomized study that used modern 
chemotherapy (oxaliplatin) suggested a benefit from preoperative chemotherapy (25% 
reduction in recurrence rate at 3 y) (31,32). A variety of chemotherapeutic regimens allows 
conversion to resectability and resections with tumor-free margins (ie, R0) in 15%–33% of 
patients, with 5-year survival rates of 30%–35%. As a result of its associated worsened 
prognosis, the presence of peritoneal carcinomatosis is a contraindication to hepatic 
metastasectomy, regardless of whether CLMs are resectable. In case of resectable CLMs, the 
presence of particular extrahepatic disease (eg, lung metastases or portal lymphadenopathy) 
does not in itself contraindicate surgical resection. In unresectable CLM, however, only 
patients with liver-only disease may eventually qualify for surgery. In patients with bilateral 
CLMs, a single-center review (33) from a prospectively maintained database of patients 
undergoing hepatic resection over an 11-year period (440 patients) showed the use of more 
parenchymal-sparing surgery (eg, wedge resections and fewer segments resected) instead of 
major, large hepatectomies is associated with improved mortality, shorter hospital stay and 
decreased blood loss without change in oncologic outcome (33).
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An international registry of patients who underwent operative treatment for CLM (34) has 
shown overall survival is 42% at 5 years and 26% at 10 years after resection (medial 
survival: 46 mo) (34). After first hepatectomy for CLMs, the 60-day operative mortality rate 
is less than 3%. Variables independently associated with poor prognosis include the 
presence of more than three metastases, bilobar metastases, and largest metastasis size 
greater than 5 cm. Preoperative systemic chemotherapy does not benefit patients with 
solitary CLM (32), but is associated with improved survival in patients with greater than five 
metastases (5-y overall survival rates, 22% vs 12% without chemotherapy) (34). Although 
neoadjuvant chemotherapy may be mandated in patients presenting with unresectable 
disease, it may be avoided in many resectable patients. These data confirm the prognostic 
importance of intrahepatic tumor burden, and indicate that the ability of preoperative 
chemotherapy to improve survival is limited to patients with multiple (ie, more than five) 
metastases (34).
Outcomes of percutaneous ablative therapies for liver metastases of CRC—
The safety and effectiveness of local thermal ablation techniques has been demonstrated in 
several clinical series since the late 1990s, mostly single-institution retrospective studies of 
radiofrequency (RF) ablation including selected nonsurgical cases in patients with limited 
disease volume (Tables 2, 3) (35–49). Despite the inclusion of nonsurgical cases and a 
relatively lower level of local control, outcomes after percutaneous ablation compared 
favorably to those after surgical resection (5-y overall survival in the 17%–37% range; 
AHRQ level II-2 evidence) (35–49). Although difficult to implement, there is a definite need 
for randomized controlled trials comparing percutaneous ablation versus surgery in selected 
patients with small size and number of CLMs that can be ablated with appropriate margins. 
Key factors contributing to CLM ablation success include small size (< 3 cm), location away 
from major vessels, and achieving clear margins (ie, A0) during local ablation (similar to the 
goal of reaching R0 tumor-free margins during surgical metastasectomy), with most 
reported rates of local recurrence in the 12%–39% range for CLMs smaller than 3 cm (50–
52).
Significant improvements in our understanding of local ablation techniques and effects have 
been made since the late 1990s. Examination of tissue collected from the ablation electrodes 
can identify viable tumor cells that highly predict local failure and shorter progression free 
survival (53). These studies set the grounds for further investigations to improve ablation 
technique, which translates into better oncologic outcomes. Also, intravenous injection of 
liposomal doxorubicin is known to enhance the ablation zone and needs further attention 
(54,55). Finally, the effects of local ablation on the immune system and the development of 
tumor specific immunity are being studied, opening a whole different field of application of 
local ablation in the treatment of patients with advanced metastatic disease (56–58). Further 
studies are warranted to better understand the effect of ablation on the immune system and 
potential benefits of this interaction specifically for mCRC patients.
Role of HAI chemotherapy for CLMs—HAI improves oncologic outcomes as a second 
line treatment for CLMs and as an adjuvant therapy after partial hepatectomy. It is typically 
combined with systemic intravenous chemotherapy rather than given alone. Different 
d’Othée et al. Page 6
J Vasc Interv Radiol. Author manuscript; available in PMC 2015 March 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
regimens are used for HAI chemotherapy, with response rates in the 64%–85% range and 1-
year survival rates between 82% and 87% (in contrast to systemic chemotherapy alone, 
which has response rates in the 11%–35% range and 1-y survival rates in the 40%–55% 
range). The regimen with the highest response rate (85%) and highest 1-year survival rate 
(87%) combines fluorodeoxyuridine and dexamethasone HAI with intravenous systemic 
chemotherapy using oxaliplatin and irinotecan (CPT-11). HAI with combined systemic 
therapy has better outcomes in chemotherapy-naive patients, in terms of response rates 
(100% vs 85% in patients who had previous systemic chemotherapy), subsequent surgical 
resection rates (57% vs 38%), and median survival time (50 mo vs 35 mo) (59). Four 
comparisons between HAI and systemic chemotherapy combined versus chemotherapy 
alone have all shown improved survival at 2 and 5 years (58–62). Disease-free survival and 
hepatic disease-free survival were both superior with HAI and systemic chemotherapy 
combined in three of these four comparisons. When HAI is used after resection, a large 
series (612 patients) also showed significantly improved survival (median: 82 mo vs 41 mo 
in the non-HAI group) (5). This conclusion is confirmed by two other studies (63,64). The 
addition of bevacizumab has added biliary toxicity without any clinical benefit (65). Despite 
these good results, the use of HAI remains limited to very few centers in the United States 
(66,67).
Outcomes of chemoembolization of liver metastases of CRC—As 
metastasectomy (with or without preoperative chemotherapy) is the first-line treatment for 
resectable metastases, the role of locoregional IO therapies is focused on unresectable CLMs 
in liver-dominant disease and when performance status and laboratory values are acceptable. 
When CLMs are not liver-dominant or if embolization is contraindicated, systemic 
chemotherapy is chosen, which may in successful cases, make CLMs again candidates for 
locoregional IO therapies. CLM smaller than 3 cm qualify for local ablation, whereas those 
between 3 and 6 cm may be treated by combined ablation and embolization; lesions larger 
than 6 cm are approached by combined embolization and systemic therapy. Techniques of 
intraarterial embolization therapy are not standardized, including bland embolization and 
chemoembolization (with one or several drugs), and various embolic agents and sizes.
Unresectable CLMs have 1- and 2-year survival rates of 55% and 33%, respectively, with 
current systemic therapies. With conventional chemoembolization, four major trials (68–71) 
showed disease control (ie, partial response and stable disease) rates of approximately 63% 
in three of these four studies (Table 4). Median survival time was 24–38 months after CLM 
onset, or 9–14 months from first chemoembolization. Although mitomycin C is often 
included in the drug regimen for conventional chemoembolization, little difference in 
outcomes is seen when adding other drugs (71).
A novel platform for chemoembolization uses drug-eluting beads loaded with irinotecan 
(DEBIRI). Complete drug loading on the microspheres can be achieved in 60–120 minutes. 
Limited clinical outcome data are available so far. An international registry (72) reported 
collective experience in 55 patients (86% lobar infusions; 30% with concurrent systemic 
chemotherapy) with response rates of 66% at 6 months and 75% at 12 months, median 
overall survival time of 19 months, and median progression-free survival time of 11 months. 
An Italian randomized trial of chemotherapy-refractory, liver-only mCRCs compared 
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DEBIRI against systemic FOLFIRI; overall and progression-free survival rates were 
significantly better in the DEBIRI arm, but both arms included additional systemic 
chemotherapies (73). In conclusion, intraarterial therapies provide disease control in the 
majority of patients with liver-dominant mCRC, and, retrospectively, survival exceeds 
expectations for systemic therapy alone. A major hurdle in evaluating the merits of any 
intraarterial therapy stems from the routine integration of multiple therapeutic modalities 
(eg, embolization, systemic chemotherapy, RF ablation, 90Y) in the same patients (ie, 
customized care), making standardization for trials difficult. Another hurdle is the difficulty 
enrolling patients who are at the early stage of first- or second-line chemotherapy, as this 
standard of care is routinely provided in the community in the outpatient setting before 
referral to a cancer center. Although the prospective evaluation of integration strategies is 
difficult, it is critical to better understand outcomes.
Outcomes of radioembolization of liver metastases of CRC—The safety/efficacy 
of radioembolization with 90Y selective internal RT in the salvage setting for unresectable 
mCRC (Table 5) has been established in multiple series of between 27 and 208 patients, 
with median survival duration between 7.9 and 14.5 months (levels II-1 and II-2 evidence) 
(74–79). These trials show clear benefits from 90Y combined with systemic chemotherapy 
compared with systemic therapy alone (improved survival and time to progression [TTP]) 
(80) or HAI alone (improved TTP) (81). Toxicity includes constitutional (15%–71%) and 
gastrointestinal disturbances (1%–7%), and radiation induced liver disease (RILD; 0%–2%).
As many chemotherapeutic agents are radiation-sensitizers, they may have a synergistic 
effect when combined with local delivery of high-dose radiation. Similar to existing 
chemoradiation protocols, the role of radioembolization as part of first or second line 
treatment for unresectable mCRC is supported by studies discerning the potential of 
combining chemotherapy with radioembolization within a short time frame (Table 6) in 
series of 19–74 patients (levels I, II-1 and II-2 evidence) (77,80–86). Compared with 
systemic therapy alone, these trials show benefit from radioembolization, although 
improvements are seen along variable dimensions across studies: some trials showed 
improvement in TTP and time to local progression (82), others in progression-free survival 
and overall survival (85).
There may be potential indications for a combined PVE and radioembolization strategy 
including adjuvant therapy (after PVE; survival benefit in unresectable patients), 
neoadjuvant therapy (before PVE; increased number of candidates for PVE), and salvage 
therapy (after PVE; no other options). Potential issues in studies include the variability in 
subjects enrolled (eg, which therapies they have undergone already), in CT volumetry 
technique, and in PVE technique.
Outcomes of external beam RI of unresectable CLM—RILD, initially mislabeled as 
“radiation hepatitis” (87), is caused by central vein occlusion, not an inflammatory response, 
leading to the loss of a lobule (88). Classic RILD could be observed in patients 2 weeks to 
90 days after whole-liver radiation to 30 Gy or more in 2 weeks. Landmark studies at the 
University of Michigan Radiation Oncology department showed that the significant volume 
effect of the liver’s parallel architecture (ie, lobules) could be exploited by using dose– 
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volume histograms and partial liver radiation treatment (89,90), eventually allowing delivery 
of fractionated doses to tumors of at least 90 Gy.
Before the availability of CT scans and three-dimensional (3D) radiation treatment planning, 
conventional whole-liver external-beam RT was used to palliate pain from expanding liver 
tumors, typically at the end of a patient’s life, with pain relief in 80% of patients (complete 
in 54%) and 30% pain-free at 6 months. In 49% of responders, liver function test results 
improved (91).
Conformal (ie, 3D) RT allows greater targeting precision, visualization of tumors, and 
protection of normal tissues with immobilization techniques and CT scans providing 3D 
data-sets. To further decrease the incidence of RILD, Robertson et al used hepatic artery 
fluorodeoxyuridine for radiosensitization in primary and metastatic liver tumors. A total of 
22 patients with mCRC were treated with a 50% objective response rate and 50% stable 
disease rate; a median survival time of 20 months, and no RILD (92). A larger phase II trial 
based on this protocol reported significantly improved overall survival and progression-free 
survival in 47 patients with mCRC (128 patients total) when the tumor dose was 60 Gy or 
higher (92). Dawson et al, also using the same protocol, treated 43 patients, most with 
mCRC, and reported a 68% response rate, with survival rates of 62% at 1 year and 14% at 2 
years (89). Intensity-modulated RT, a more sophisticated form of 3D RT, has as yet not been 
successfully adapted to liver RT for several reasons, most notably abdominal organ motion 
(93).
Stereotactic body RT allows highly conformable radiation fields, but delivers one to five 
total fractions of external-beam RT over a period of 1–2 weeks by using specialized 
immobilization techniques, respiratory gating, limited respiratory motion via abdominal 
compression, and implanted fiducial markers in the liver to enhance targeting and imaging 
during treatment. Three recent reports of stereotactic body RT, including its use in CLM, 
show promising results for tumor control and low risk of toxicity when the lesions are small 
and number three or fewer per patient. The phase I/II study of Herfarth et al in 37 patients 
(60 tumors, of which 30 patients had mCRC) showed a local control rate of 81% at 18 
months (94). Rusthoven et al reported a six-institution phase I/II study of 47 patients with 
liver metastases (15 with mCRC) and showed a local control rate of 92% at 2 years and no 
RILD (95). Lee et al reported a single-institution phase I study with a local control rate of 
71% at 1 year in 40 patients with mCRC (68 patients total) (96).
Ongoing trials for patients with CRC liver metastases—As of the date of the RCP 
Meeting, there were 528 trials on mCRC listed on www.ClinicalTrials.gov, 28% of which 
were currently open. More than 80% evaluated or compared systemic chemotherapy 
regimens. Trials studying liver-targeted IO treatments and including specifically mCRC 
patients consisted of 29 studies on RF ablation (one randomized), six on irinotecan-eluting 
beads (two randomized), 18 on SIR Spheres (SirTex, Lane Cove, Australia) 
radioembolization (two randomized), and 29 on Thera-Sphere (Nordion, Ottawa, Ontario, 
Canada) radioembolization (none randomized). Most of these studies focus on unresectable 
metastases and are industry-sponsored. All the randomized trials compare IO therapies with 
a systemic chemotherapy regimen, but none of them compare different IO treatments. There 
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remain many opportunities for important trials to be done to define the role of IO therapies, 
as there are no prospective randomized clinical trials (i) comparing radioembolization to 
chemoembolization, or radioembolization or chemoembolization to HAI chemotherapy, (ii) 
comparing RF ablation to surgical resection or RF ablation to systemic chemotherapy, or 
(iii) studying the potential synergy between local ablative therapies and regional intraarterial 
treatments.
Panel Discussion/Prioritization
After the round-robin discussion, the panelists voted to produce a ranking list of priority 
research topics as described earlier; members from governmental agencies and from industry 
did not vote. The final top three research topics (Table 7) are: (i) studies to evaluate the 
benefit of combining new imaging criteria with fine-needle aspiration or biopsy, (ii) studies 
to establish new or modified disease status criteria (replacing RECIST), and (iii) studies 
enrolling selected subsets of patients (eg, those with KRAS mutations) to undergo 
radioembolization, RF ablation, or both. The top two were consolidated into one topic after 
further discussion. The RCP panelists or SIR members not attending the RCP may apply to 
assist with the development of a research protocol and/or grant application on any of these 
two top priority topics so that they may pursue federal and/or industry funding for the trial.
DISCUSSION
Systemic chemotherapy remains the first-line treatment given to patients with unresectable 
mCRC. Bevacizumab and cetuximab add only modest additional benefit to systemic 
chemotherapy. However, available alternatives have high success rates, including external-
beam RT, intraarterial hepatic chemotherapy, and radioembolization. The use of these 
alternatives has remained limited to the palliative setting. There are, however, selected 
subsets of patients in whom results of systemic therapy are poor: for example, those with 
KRAS mutations (who represent 35%–40% of all CRC patients) do not show a benefit from 
cetuximab or panitumumab and show a low response to second-line FOLFIRI alone (4%). In 
such subsets, IO treatments may have a role to play. BRAF genomic tumor profiling may 
also be an important parameter that needs additional evaluation. In the NCCN Guidelines, 
testing tumor KRAS gene status is recommended in any mCRC patient at the time of 
diagnosis of metastatic disease (1). While awaiting the results of ongoing investigations, the 
current approach of using systemic therapy as first-line treatment to assess tumor biology 
and responsiveness remains the standard approach to unresectable mCRC (1,2,34). 
Similarly, an “ablate and wait” approach has been suggested (42). Finally, not only liver but 
also other metastases (eg, lung) may benefit from locoregional therapies.
There remain several important hurdles to the implementation of meaningful randomized 
controlled trials evaluating or comparing IO therapies for mCRC. First, the criteria for 
unresectability of liver metastases need to be refined as they vary widely based on a number 
of factors, some of which do not appear fully understood yet. Creating a platform to gather 
opinions from surgeons on whether a given patient is a candidate for resection is suggested, 
although its practical implementation may be difficult.
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Second, better assessment tools of nonsurvival end-points need to be developed, and their 
predictive value on survival will need to be evaluated. The creation of a clinical prognostic 
risk score to predict survival outcomes (or pathologic response) before any IO treatment is a 
much desired tool. There is indeed very poor correlation between survival and imaging 
outcomes. Potentially useful predictors of survival after locoregional therapies deserve 
further investigation (similar to the use of the FLR before potential hepatectomy). Also, 
imaging alone after locoregional therapies, even with combined positron emission 
tomography-CT, seems unreliable and often underestimates residual disease, as seen 
intraoperatively. Searching for improved imaging criteria to assess disease status and 
response to treatment seemed a crucial initial step to the panel members. In addition, they 
also favored combining such criteria with more frequent tissue sampling before and after 
treatment, which can help answer multiple questions and guide treatment. There are multiple 
potential merits to this combined imaging/tissue diagnosis approach: (i) 
immunohistochemical analyses of cells adherent to RF ablation probes at the end of ablation 
procedures can help predict local tumor progression (53); (ii) post-RF ablation fine needle 
aspirations (53) have also been shown to improve detection of local recurrences with no 
added morbidity or mortality; (iii) biopsy of the normal parenchyma helps in assessing the 
degree of liver damage induced by previous systemic chemotherapy. Several panel members 
expressed concern that many patients become candidates for radioembolization only after 
having been treated with multiple lines of chemotherapy, which have caused an 
indeterminate amount of liver damage that cannot be quantified without obtaining pre-
radioembolization biopsies; (iv) postradioembolization biopsies may also be helpful to better 
assess liver parenchymal damage; (v) biopsies of CLMs can also help establish the biologic 
profile of tumors before and after locoregional therapies. Analyses of deoxyribonucleic acid 
from biopsy specimens of CLM show that tumoral mutations before and after treatment are 
an important predictor of outcomes.
In conclusion, the top research priorities identified by this process clearly stress the need to 
develop better response evaluation tool(s) tailored to IO therapies before moving forward 
with future comparative trials that may help distinguish which treatments work best in which 
patient populations. The ability of such tool(s) to predict survival would be a major asset. 
Therapeutic studies should focus on unresectable CLM, and trials enrolling selected patients 
subsets, such as those with KRAS mutations, were also identified as another important topic 
for future research.
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ABBREVIATIONS
AHRQ Agency for Healthcare Research and Quality
CLM colorectal liver metastases
CRC colorectal cancer
DEBIRI drug-eluting beads loaded with irinotecan
FLR future liver remnant
FOLFIRI folinic acid/5-fluorouracil/irinotecan [systemic chemotherapy regimen]
FOLFOX folinic acid, fluorouracil, and oxaliplatin [systemic chemotherapy regimen]
HAI hepatic arterial infusion
IO interventional oncology
mCRC metastatic colorectal cancer
NCCN National Comprehensive Cancer Network
PVE portal vein embolization
RCP Research Consensus Panel
RECIST response evaluation criteria in solid tumors
RF radiofrequency
RILD radiation-induced liver disease
RT radiation therapy
3D three-dimensional
TTP time to progression
VEGF anti-vascular endothelial growth factor
References
1. Engstrom PF, Arnoletti JP, Benson AB III, et al. NCCN Clinical Practice Guidelines in Oncology: 
colon cancer. J Natl Compr Canc Netw. 2009; 7:778–831. [PubMed: 19755046] 
2. Engstrom PF, Arnoletti JP, Benson AB III, et al. NCCN Clinical Practice Guidelines in Oncology: 
rectal cancer. J Natl Compr Canc Netw. 2009; 7:838–881. [PubMed: 19755047] 
3. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and 
management of liver metastases from colorectal cancer. Ann Surg. 2006; 244:254–259. [PubMed: 
16858188] 
4. Vogt P, Raab R, Ringe B, Pichlmayr R. Resection of synchronous liver metastases from colorectal 
cancer. World J Surg. 1991; 15:62–67. [PubMed: 1994607] 
5. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of 
colorectal liver metastases defines cure. J Clin Oncol. 2007; 25:4575–4580. [PubMed: 17925551] 
d’Othée et al. Page 12
J Vasc Interv Radiol. Author manuscript; available in PMC 2015 March 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
6. Adam R. The importance of visceral metastasectomy in colorectal cancer. Ann Oncol. 2000; 
11(suppl 3):29–36. [PubMed: 11079115] 
7. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with 
fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised 
trial. Lancet. 2000; 355:1041–1047. [PubMed: 10744089] 
8. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added 
to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J 
Clin Oncol. 2000; 18:136–147. [PubMed: 10623704] 
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and 
leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335–2342. [PubMed: 
15175435] 
10. Cascinu S, Berardi R, Salvagni S, et al. A combination of gefitinib and FOLFOX-4 as first-line 
treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including 
a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer. 
2008; 98:71–76. [PubMed: 18059397] 
11. Owens, DK.; Lohr, KN.; Atkins, D., et al. Grading the strength of a body of evidence when 
comparing medical interventions. Rockville, MD: Agency for Healthcare Research and Quality; 
2009. 
12. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic 
metastases from colorectal cancer. A comparison with resective treatment. Ann Surg. 1984; 
199:502–508. [PubMed: 6721600] 
13. Vauthey JN, Chaoui A, Do KA, et al. Standardized measurement of the future liver remnant prior 
to extended liver resection: methodology and clinical associations. Surgery. 2000; 127:512–519. 
[PubMed: 10819059] 
14. Vauthey JN, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver 
volume in Western adults. Liver Transpl. 2002; 8:233–240. [PubMed: 11910568] 
15. Kishi Y, Abdalla EK, Chun YS, et al. Three hundred and one consecutive extended right 
hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg. 2009; 
250:540–548. [PubMed: 19730239] 
16. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients 
with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch 
Surg. 2002; 137:675–680. [PubMed: 12049538] 
17. Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy 
justified? Ann Surg. 2004; 239:722–730. [PubMed: 15082977] 
18. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases 
downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004; 240:644–
657. [PubMed: 15383792] 
19. Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the 
feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann 
Surg. 2000; 232:665–672. [PubMed: 11066138] 
20. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an 
increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006; 
24:2065–2072. [PubMed: 16648507] 
21. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does 
not affect liver regeneration after portal vein embolization in the treatment of colorectal liver 
metastases. Ann Surg Oncol. 2008; 15:2765–2772. [PubMed: 18636296] 
22. Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic functional 
reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997; 
26:1176–1181. [PubMed: 9362359] 
23. Elias D, Ouellet JF, De Baere T, Lasser P, Roche A. Preoperative selective portal vein 
embolization before hepatectomy for liver metastases: long-term results and impact on survival. 
Surgery. 2002; 131:294–299. [PubMed: 11894034] 
24. Capussotti L, Ferrero A, Vigano L, Ribero D, Lo Tesoriere R, Polastri R. Major liver resections 
synchronous with colorectal surgery. Ann Surg Oncol. 2007; 14:195–201. [PubMed: 17080238] 
d’Othée et al. Page 13
J Vasc Interv Radiol. Author manuscript; available in PMC 2015 March 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
25. Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from 
colorectal carcinoma. Ann Surg. 2000; 231:743–751. [PubMed: 10767796] 
26. Brouquet A, Mortenson MM, Vauthey JN, et al. Surgical strategies for synchronous colorectal 
liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll 
Surg. 2010; 210:934–941. [PubMed: 20510802] 
27. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin. 1999; 49:231–255. 
[PubMed: 11198884] 
28. Blazer DG III, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new 
outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008; 26:5344–
5351. [PubMed: 18936472] 
29. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography 
morphologic criteria with pathologic response and survival in patients treated with bevacizumab 
for colorectal liver metastases. JAMA. 2009; 302:2338–2344. [PubMed: 19952320] 
30. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is 
associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 
27:3677–3683. [PubMed: 19470929] 
31. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and 
surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 
Intergroup trial 40983): a randomised controlled trial. Lancet. 2008; 371:1007–1016. [PubMed: 
18358928] 
32. Adam R, Bhangui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, 
metachronous, colorectal liver metastases? Ann Surg. 2010; 252:774–787. [PubMed: 21037433] 
33. Gold JS, Are C, Kornprat P, et al. Increased use of parenchymal-sparing surgery for bilateral liver 
metastases from colorectal cancer is associated with improved mortality without change in 
oncologic outcome: trends in treatment over time in 440 patients. Ann Surg. 2008; 247:109–117. 
[PubMed: 18156930] 
34. Adam R, Aloia T, Figueras J, et al. LiverMetSurvey: analysis of clinicopathologic factors 
associated with the efficacy of preoperative chemotherapy in 2,122 patients with colorectal liver 
metastases. J Clin Oncol. 2006; 24(18 suppl):151s. Abstract 3521. 
35. Elias D, De Baere T, Smayra T, Ouellet JF, Roche A, Lasser P. Percutaneous radiofrequency 
thermoablation as an alternative to surgery for treatment of liver tumour recurrence after 
hepatectomy. Br J Surg. 2002; 89:752–756. [PubMed: 12027986] 
36. Vogl TJ, Straub R, Eichler K, Sollner O, Mack MG. Colorectal carcinoma metastases in liver: 
laser-induced interstitial thermotherapy–local tumor control rate and survival data. Radiology. 
2004; 230:450–458. [PubMed: 14688400] 
37. Hur H, Ko YT, Min BS, et al. Comparative study of resection and radiofrequency ablation in the 
treatment of solitary colorectal liver me-tastases. Am J Surg. 2009; 197:728–736. [PubMed: 
18789428] 
38. Adam R, Hagopian EJ, Linhares M, et al. A comparison of percutaneous cryosurgery and 
percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg. 2002; 137:1332–
1339. [PubMed: 12470093] 
39. Gillams AR, Lees WR. Five-year survival following radiofrequency ablation of small, solitary, 
hepatic colorectal metastases. J Vasc Interv Radiol. 2008; 19:712–717. [PubMed: 18440460] 
40. Helmberger T, Holzknecht N, Schopf U, et al. Radiofrequency ablation of liver metastases. 
Technique and initial results. Radiologe. 2001; 41:69–76. [PubMed: 11220100] 
41. Lencioni R, Goletti O, Armillotta N, et al. Radio-frequency thermal ablation of liver metastases 
with a cooled-tip electrode needle: results of a pilot clinical trial. Eur Radiol. 1998; 8:1205–1211. 
[PubMed: 9724440] 
42. Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency 
ablation of liver metastases in potential candidates for resection: the “test-of-time approach”. 
Cancer. 2003; 97:3027–3035. [PubMed: 12784338] 
43. Sofocleous CT, Petre EN, Gonen M, et al. CT-guided radiofrequency ablation as a salvage 
treatment of colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Interv 
Radiol. 2011; 22:755–761. [PubMed: 21514841] 
d’Othée et al. Page 14
J Vasc Interv Radiol. Author manuscript; available in PMC 2015 March 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
44. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radiofrequency ablation of hepatic 
metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001; 221:159–
166. [PubMed: 11568334] 
45. White RR, Avital I, Sofocleous CT, et al. Rates and patterns of recurrence for percutaneous 
radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J 
Gastrointest Surg. 2007; 11:256–263. [PubMed: 17458595] 
46. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated 
with radiofrequency ablation. Eur Radiol. 2009; 19:1206–1213. [PubMed: 19137310] 
47. Machi J, Oishi AJ, Sumida K, et al. Long-term outcome of radiofrequency ablation for 
unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and 
effectiveness in first- and second-line management. Cancer J. 2006; 12:318–326. [PubMed: 
16925977] 
48. Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection and 
radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg. 2003; 
90:1240–1243. [PubMed: 14515293] 
49. Sørensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: 
long-term survival. Acta Radiol. 2007; 48:253–258. [PubMed: 17453491] 
50. Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment 
success as defined by histologic examination of the explanted liver. Radiology. 2005; 234:954–
960. [PubMed: 15681691] 
51. Mulier S, Ni Y, Jamart J, Michel L, Marchal G, Ruers T. Radiofrequency ablation versus resection 
for resectable colorectal liver metastases: time for a randomized trial? Ann Surg Oncol. 2008; 
15:144–157. [PubMed: 17906898] 
52. Poon RT, Ng KK, Lam CM, et al. Learning curve for radiofrequency ablation of liver tumors: 
prospective analysis of initial 100 patients in a tertiary institution. Ann Surg. 2004; 239:441–449. 
[PubMed: 15024304] 
53. Sofocleous CT, Nascimento RG, Petrovic LM, et al. Histopathologic and immunohistochemical 
features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help 
predict local tumor progression: initial results. Radiology. 2008; 249:364–374. [PubMed: 
18796687] 
54. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure 
rate of radiofrequency ablation in liver cancer. Future Oncol. 2011; 7:937–945. [PubMed: 
21823888] 
55. Solazzo SA, Ahmed M, Schor-Bardach R, et al. Liposomal doxorubicin increases radiofrequency 
ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and 
accelerating apoptotic pathways. Radiology. 2010; 255:62–74. [PubMed: 20160000] 
56. Hansler J, Wissniowski TT, Schuppan D, et al. Activation and dramatically increased cytolytic 
activity of tumor specific T lymphocytes after radio-frequency ablation in patients with 
hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol. 2006; 12:3716–
3721. [PubMed: 16773688] 
57. Ravindranath MH, Wood TF, Soh D, et al. Cryosurgical ablation of liver tumors in colon cancer 
patients increases the serum total ganglioside level and then selectively augments antiganglioside 
IgM. Cryobiology. 2002; 45:10–21. [PubMed: 12445546] 
58. Zhang Y, Deng J, Feng J, Wu F. Enhancement of antitumor vaccine in ablated hepatocellular 
carcinoma by high-intensity focused ultrasound. World J Gastroenterol. 2010; 16:3584–3591. 
[PubMed: 20653069] 
59. Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery 
infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from 
colorectal carcinoma. J Clin Oncol. 2009; 27:3465–3471. [PubMed: 19470932] 
60. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered 
either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via 
hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. 
J Clin Oncol. 2000; 18:243–254. [PubMed: 10637236] 
d’Othée et al. Page 15
J Vasc Interv Radiol. Author manuscript; available in PMC 2015 March 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
61. Lygidakis NJ, Sgourakis G, Vlachos L, et al. Metastatic liver disease of colorectal origin: the value 
of locoregional immunochemotherapy combined with systemic chemotherapy following liver 
resection. Results of a prospective randomized study. Hepatogastroenterology. 2001; 48:1685–
1691. [PubMed: 11813601] 
62. Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 
in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann 
Surg Oncol. 2008; 15:219–226. [PubMed: 17896145] 
63. House MG, Kemeny NE, Gönen M, et al. Comparison of adjuvant systemic chemotherapy with or 
without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal 
cancer. Ann Surg. 2011; 254:851–856. [PubMed: 21975318] 
64. Ito H, Are C, Gönen M, et al. Effect of postoperative morbidity on long-term survival after hepatic 
resection for metastatic colorectal cancer. Ann Surg. 2008; 247:994–1002. [PubMed: 18520227] 
65. Kemeny NE, Jarnagin WR, Capanu M, et al. Randomized phase II trial of adjuvant hepatic arterial 
infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic 
metastases from colorectal cancer. J Clin Oncol. 2011; 29:884–889. [PubMed: 21189384] 
66. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection 
of hepatic metastases from colorectal cancer. N Engl J Med. 1999; 341:2039–2048. [PubMed: 
10615075] 
67. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med. 2005; 
352:734–735. [PubMed: 15716576] 
68. Sanz-Altamira PM, Spence LD, Huberman MS, et al. Selective chemoembolization in the 
management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon 
Rectum. 1997; 40:770–775. [PubMed: 9221850] 
69. Tellez C, Benson AB III, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of 
metastatic colorectal carcinoma to the liver and review of the literature. Cancer. 1998; 82:1250–
1259. [PubMed: 9529016] 
70. Albert M, Kiefer MV, Sun W, et al. Chemoembolization of colorectal liver metastases with 
cisplatin, doxorubicin, mitomycin C, Ethiodol, and polyvinyl alcohol. Cancer. 2011; 117:343–352. 
[PubMed: 20830766] 
71. Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial 
chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. 
Radiology. 2009; 250:281–289. [PubMed: 19092099] 
72. Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, 
irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic 
chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011; 18:192–198. [PubMed: 
20740319] 
73. Fiorentini G, Aliberti C, Tilli M, et al. Evaluation of a phase III clinical trial comparing 
transarterial chemoembolisation (TACE) using irinotecan-loaded polyvinyl alcohol microspheres 
(Debiri) vs systemic chemotherapy FOLFIRI (CT) for the treatment of unresectable metastases to 
the liver (LM) in patients with advanced colorectal cancer (MCRC). Cardiovasc Intervent Radiol. 
2011; 34:599. Abstract P-286. 
74. Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y microsphere (TheraSphere) treatment for 
unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 
135–150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and 
computed tomographic imaging. J Vasc Interv Radiol. 2005; 16:1641–1651. [PubMed: 16371530] 
75. Jakobs TF, Hoffmann RT, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-
refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008; 19:1187–1195. [PubMed: 
18656012] 
76. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable 
colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006; 65:412–
425. [PubMed: 16690429] 
77. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic 
metastases using yttrium-90 microspheres. Cancer. 2009; 115:1849–1858. [PubMed: 19267416] 
d’Othée et al. Page 16
J Vasc Interv Radiol. Author manuscript; available in PMC 2015 March 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
78. Cianni R, Urigo C, Notarianni E, et al. Radioembolisation using yttrium 90 (Y-90) in patients 
affected by unresectable hepatic metastases. Radiol Med. 2010; 115:619–633. [PubMed: 
20091135] 
79. Evans KA, Richardson MG, Pavlakis N, Morris DL, Liauw W, Bester L. Survival outcomes of a 
salvage patient population after radioembolization of hepatic metastases with yttrium-90 
microspheres. J Vasc Interv Radiol. 2010; 21:1521–1526. [PubMed: 20813542] 
80. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus 
fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in 
advanced colorectal cancer. J Surg Oncol. 2004; 88:78–85. [PubMed: 15499601] 
81. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. 
chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. 
Ann Oncol. 2001; 12:1711–1720. [PubMed: 11843249] 
82. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous 
fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-
limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010; 
28:3687–3694. [PubMed: 20567019] 
83. Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from 
colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, 
fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007; 25:1099–1106. [PubMed: 
17369573] 
84. van Hazel GA, Pavlakis N, Goldstein D, et al. Treatment of fluorouracilrefractory patients with 
liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant 
systemic irinotecan chemotherapy. J Clin Oncol. 2009; 27:4089–4095. [PubMed: 19652069] 
85. Kosmider S, Tan TH, Yip D, Dowling R, Lichtenstein M, Gibbs P. Radioembolization in 
combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal 
cancer. J Vasc Interv Radiol. 2011; 22:780–786. [PubMed: 21515072] 
86. Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus 
best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant 
colorectal metastases. Cardiovasc Intervent Radiol. 2011 Jul 29. Epub ahead of print. 10.1007/
s00270-011-0234-7
87. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium 
Ther Nucl Med. 1965; 93:200–208.
88. Reed GB Jr, Cox AJ Jr. The human liver after radiation injury. A form of veno-occlusive disease. 
Am J Pathol. 1966; 48:597–611. [PubMed: 5327788] 
89. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic 
artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000; 
18:2210–2218. [PubMed: 10829040] 
90. Lawrence TS, Ten Haken RK, Kessler ML, et al. The use of 3-D dose volume analysis to predict 
radiation hepatitis. Int J Radiat Oncol Biol Phys. 1992; 23:781–788. [PubMed: 1618671] 
91. Leibel SA, Pajak TF, Massullo V, et al. A comparison of misonidazole sensitized radiation therapy 
to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy 
Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys. 1987; 13:1057–1064. 
[PubMed: 3597149] 
92. Robertson JM, Lawrence TS, Walker S, Kessler ML, Andrews JC, Ensminger WD. The treatment 
of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. Int J 
Radiat Oncol Biol Phys. 1995; 32:445–450. [PubMed: 7751185] 
93. Cheng JC, Wu JK, Huang CM, et al. Dosimetric analysis and comparison of three-dimensional 
conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular 
carcinoma and radiation-induced liver disease. Int J Radiat Oncol Biol Phys. 2003; 56:229–234. 
[PubMed: 12694843] 
94. Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors: 
results of a phase I/II trial. J Clin Oncol. 2001; 19:164–170. [PubMed: 11134209] 
d’Othée et al. Page 17
J Vasc Interv Radiol. Author manuscript; available in PMC 2015 March 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
95. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic 
body radiation therapy for liver metastases. J Clin Oncol. 2009; 27:1572–1578. [PubMed: 
19255321] 
96. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy 
of liver metastases. J Clin Oncol. 2009; 27:1585–1591. [PubMed: 19255313] 
d’Othée et al. Page 18
J Vasc Interv Radiol. Author manuscript; available in PMC 2015 March 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
d’Othée et al. Page 19
Table 1
United States Agency for Healthcare Research and Quality Classification of Levels of Evidence (11)
Level Description
 I Evidence from randomized controlled trial(s)
 II-1 Evidence from controlled trial(s) without randomization
 II-2 Evidence from cohort or case-control analytic studies, preferably from more than one center or research group
 II-3 Evidence from comparisons between times or places with or without the intervention; dramatic results in uncontrolled experiments 
could be included here
 III Opinions of respected authorities, based on clinical experience; descriptive studies or reports of expert committees
Note.—Modified from Owens et al (11).
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Table 2
Outcomes after Percutaneous Local Ablation for Liver Metastases of CRC: Survival (35–37,39,43,44,47)
Study, Year Modality No. of Pts./Lesions Level of Evidence Median OS after Ablation (mo)
Hur et al (37), 2009 RF     25/25 II-2
  41*
Solbiati et al (44), 2001 RF (P)   117/179 II-2 36
Gillams and Lees (39), 2009† RF (P)   309/617 II-2
  32‡
Elias et al (35), 2002 RF (P)     29/NA II-2 > 24§  
Oshowo et al (48), 2003† RF     25/25 II-2
  37‖
Machi et al (47), 2006 RF   100/507 (42%P) II-2 28
Vogl et al (36), 2004 LITT (P)   603/1,801 II-2 35
Sorensen et al (49), 2007 RF (P)   100/332 II-2 32
Sofocleous et al (43), 2011 RF (P)     56/71 II-2
  31¶
Note.—CRC = colorectal cancer, LITT = laser-induced interstitial thermotherapy, NA = not available, OS = overall survival, P = percutaneous, RF 
= radiofrequency.
*Series includes 12 percutaneous and 13 intraoperative RF ablation cases; resection arm of this study (42 patients, 42 lesions) showed medial OS 
duration of 60 mo.
†
Partially redundant series.
‡
Medial survival time was 36 mo in 123 patients with ≤ 5 colorectal metastases ≤ 5 cm in size.
§Series on RF ablation of postresection local recurrences (47 patients, 65 lesions), including 29 non-CRC cases; summary median survival includes 
non-CRC cases.
‖
Resection arm of this study (20 patients, 20 lesions) showed medial OS duration of 41 mo.
¶Salvage RF ablation for colorectal metastases developing after surgical resection.
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Table 7
Results of Voting Tally
Rank List of Consolidated Priority Topics Score
  1 Study to evaluate benefit of combining new imaging criteria with FNA 46
  2 Studies to establish new/modified disease status criteria (EASL/RECIST) 48
  3 Studies enrolling selected subsets of patients (eg, KRAS mutants) to radioembolization, RF ablation, or both 50
  4 RCT comparing surgical resection vs ablation for small CLM 53
  5 Studies investigating correlation between TTP and OS 59
  6 RCT comparing systemic chemotherapy with/without chemoembolization 63
  7 RCT comparing radioembolization plus HAI chemotherapy (plus IV FOLFOX) vs DEBIRI (plus IV FOLFOX) 65
  8 Studies on standardization of portal vein embolization 68
  9 RCT comparing DEBIRI chemoembolization vs radioembolization 70
10 Studies investigating dose determination for radioembolization (animal study; dose escalation) 71
11 Building database or voting approach to determine surgical resectability 74
12 RCT comparing DEBIRI chemoembolization vs systemic chemotherapy 75
13 Studies of FLR as surrogate for survival 77
Note.—CLM = colorectal metastases, DEBIRI = drug-eluting beads loaded with irinotecan, EASL = European Association for the Study of the 
Liver, FLR = future liver remnant, FNA = fine needle aspiration, FOLFOX = folinic acid, fluorouracil, and oxaliplatin [systemic chemotherapy 
regimen], HAI = hepatic arterial infusion, IV = intravenous, OS = overall survival, RCT = randomized controlled trial, RECIST = Response 
Evaluation Criteria In Solid Tumors, RF = radiofrequency, TTP = time to progression.
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